CARDIOL THERAPEUTICS INC

CARDIOL THERAPEUTICS INC
WKN: A2PA9E | ISIN: CA14161Y2006 | FSE: CT9 | TSX: CRDL | NASDAQ: CRDL

Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease

The Company brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific and Business Advisory Boards comprising business and thought leaders with extensive industry experience and expertise in commercializing proprietary drugs.

Cardiol has received clearance from the U.S. FDA for its Investigational New Drug (IND) application that is being investigated in a Phase II/III outcomes study (the LANCER Trial). A double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19 who have a prior history of, or risk factors for cardiovascular disease (CVD), and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.

CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC free (<10 ppm).

Cardiol has also received clearance from the FDA for its application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age, In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure – a leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

The Company has research collaborations focused on developing a subcutaneous cannabidiol formulation for heart failure underway at international centers of excellence, including the Houston Methodist DeBakey Heart & Vascular Center, the University of Alberta, and TecSalud del Tecnológico de Monterrey, Mexico.

More Information: https://www.cardiolrx.com/

Speaker at IIF is David Elsley – CEO Cardiol Therapeutics Inc.

*CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore